alvimopan indications/contra

Stem definitionDrug idCAS RN
143 156053-89-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • alvimopan dihydrate
  • alvimopan anhydrous
  • LY246736
  • LY-246736
  • alvimopan
  • entereg
mu opioid receptor antagonist; intended to treat constipation in patients taking opiates for pain
  • Molecular weight: 424.54
  • Formula: C25H32N2O4
  • CLOGP: 2.16
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 89.87
  • ALOGS: -4.71
  • ROTB: 8

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
May 20, 2008 FDA CUBIST PHARMS

FDA Adverse Event Reporting System

None

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC A06AH02 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR CONSTIPATION
DRUGS FOR CONSTIPATION
Peripheral opioid receptor antagonists
MeSH PA D005765 Gastrointestinal Agents
FDA EPC N0000175691 Opioid Antagonist
FDA MoA N0000000154 Opioid Antagonists

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Postoperative ileus indication 235833007
Myocardial infarction contraindication 22298006 DOID:5844
Hepatic failure contraindication 59927004
Chronic renal failure syndrome contraindication 90688005 DOID:784

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.38 acidic
pKa2 9.82 acidic
pKa3 9.22 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
12MG ENTEREG CUBIST PHARMS N021775 May 20, 2008 RX CAPSULE ORAL 6469030 Nov. 29, 2020 A METHOD OF TREATING OR PREVENTING ILEUS
12MG ENTEREG CUBIST PHARMS N021775 May 20, 2008 RX CAPSULE ORAL 8645160 June 18, 2029 TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
12MG ENTEREG CUBIST PHARMS N021775 May 20, 2008 RX CAPSULE ORAL 8946262 Feb. 12, 2030 A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY
12MG ENTEREG CUBIST PHARMS N021775 May 20, 2008 RX CAPSULE ORAL 8112290 July 31, 2030 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mu-type opioid receptor GPCR ANTAGONIST Ki 9.40 WOMBAT-PK CHEMBL
Kappa-type opioid receptor GPCR Ki 7 CHEMBL
Delta-type opioid receptor GPCR Ki 7.92 CHEMBL

External reference:

scroll-->
IDSource
4025232 VUID
N0000179783 NUI
C1508750 UMLSCUI
7471 IUPHAR_LIGAND_ID
D02878 KEGG_DRUG
677C126AET UNII
170098-38-1 SECONDARY_CAS_RN
4025232 VANDF
25351 MMSL
d07141 MMSL
480639 RXNORM
437886007 SNOMEDCT_US
437917007 SNOMEDCT_US
N0000171764 NDFRT
N0000179783 NDFRT
012792 NDDF
CHEMBL270190 ChEMBL_ID
5488548 PUBCHEM_CID
C419502 MESH_SUPPLEMENTAL_RECORD_UI
DB06274 DRUGBANK_ID
8245 INN_ID
CHEBI:135686 CHEBI

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Entereg HUMAN PRESCRIPTION DRUG LABEL 1 67919-020 CAPSULE 12 mg ORAL NDA 17 sections